Boston Scientific Co. (NYSE:BSX - Free Report) - Analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Boston Scientific in a research note issued on Monday, June 16th. Leerink Partnrs analyst M. Kratky forecasts that the medical equipment provider will post earnings per share of $0.73 for the quarter. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Boston Scientific's current full-year earnings is $2.85 per share. Leerink Partnrs also issued estimates for Boston Scientific's Q3 2025 earnings at $0.72 EPS, Q4 2025 earnings at $0.73 EPS, Q1 2026 earnings at $0.79 EPS, Q2 2026 earnings at $0.82 EPS, Q3 2026 earnings at $0.84 EPS, Q4 2026 earnings at $0.90 EPS, FY2026 earnings at $3.36 EPS and FY2027 earnings at $3.88 EPS.
Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same period last year, the firm posted $0.56 EPS. The firm's revenue for the quarter was up 20.9% on a year-over-year basis.
Other equities analysts also recently issued reports about the stock. Needham & Company LLC restated a "buy" rating and set a $115.00 target price on shares of Boston Scientific in a report on Wednesday, May 28th. Citigroup reissued a "buy" rating and issued a $125.00 target price (up from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Argus set a $130.00 target price on shares of Boston Scientific in a research report on Tuesday, February 18th. Royal Bank of Canada raised their target price on shares of Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Finally, Truist Financial raised their target price on shares of Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a research report on Thursday, April 24th. Twenty-two investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $116.09.
Check Out Our Latest Research Report on BSX
Boston Scientific Stock Performance
NYSE:BSX opened at $101.49 on Tuesday. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The firm has a 50-day moving average price of $101.25 and a two-hundred day moving average price of $98.87. Boston Scientific has a twelve month low of $71.88 and a twelve month high of $107.17. The company has a market capitalization of $150.15 billion, a P/E ratio of 81.19, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68.
Insider Activity
In other Boston Scientific news, EVP Arthur C. Butcher sold 17,314 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the sale, the executive vice president now directly owns 22,235 shares in the company, valued at approximately $2,269,304.10. The trade was a 43.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Vance R. Brown sold 4,826 shares of the company's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president now directly owns 36,193 shares of the company's stock, valued at $3,441,592.37. The trade was a 11.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 411,970 shares of company stock valued at $42,406,693. 0.50% of the stock is currently owned by company insiders.
Institutional Trading of Boston Scientific
Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank Pictet & Cie Europe AG raised its holdings in Boston Scientific by 40.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after buying an additional 21,173 shares during the period. Kentucky Retirement Systems Insurance Trust Fund increased its holdings in shares of Boston Scientific by 8.4% in the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 47,284 shares of the medical equipment provider's stock valued at $4,223,000 after purchasing an additional 3,683 shares during the period. Illinois Municipal Retirement Fund increased its holdings in shares of Boston Scientific by 13.9% in the 4th quarter. Illinois Municipal Retirement Fund now owns 184,802 shares of the medical equipment provider's stock valued at $16,507,000 after purchasing an additional 22,504 shares during the period. CIBC Asset Management Inc increased its holdings in shares of Boston Scientific by 4.4% in the 4th quarter. CIBC Asset Management Inc now owns 242,485 shares of the medical equipment provider's stock valued at $21,659,000 after purchasing an additional 10,181 shares during the period. Finally, Van ECK Associates Corp increased its holdings in shares of Boston Scientific by 1.9% in the 4th quarter. Van ECK Associates Corp now owns 58,984 shares of the medical equipment provider's stock valued at $5,268,000 after purchasing an additional 1,090 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.
Boston Scientific Company Profile
(
Get Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
